Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Windtree Therapeutics, Inc. (WINT)
USD0.01
0.00 (-8.40%)
US OTC Healthcare Biotechnology
Address
2600 Kelly Road 18976-3622
Warrington, PA, US
Warrington, PA, US
CEO
Jed A. Latkin
Website
windtreetx.com
IPO
1995-08-07
CIK 946486 ISIN US97382D6004
Also trades on
Other OTC · WINT (USD)
Other OTC · WINTW (USD)
Description
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical firm primarily dedicated to developing therapies for acute cardiovascular ailments, and secondarily for acute pulmonary diseases. Its prominent therapeutic programs include istaroxime, undergoing Phase IIb clinical trials for acute decompensated heart failure and Phase IIa for early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant in Phase IIb for respiratory distress syndrome in preterm infants; Lyophilized KL4 surfactant, in Phase IIa trials for lung injury stemming from COVID-19; and Rostafuroxin, in Phase IIb for genetically associated hypertension. The company maintains collaborations, including one with Universita degli Studi di Milano-Bicocca for the discovery and advancement of novel SERCA2a compounds targeting chronic and acute human heart failure. It also holds a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and commercialization of a portfolio of potential KL4 surfactant products, and a collaboration with Battelle Memorial Institute to further develop its ADS for its Phase III program. Established in 1992 as Discovery Laboratories, Inc., the company rebranded as Windtree Therapeutics, Inc. in April 2016. It is headquartered in Warrington, Pennsylvania, and operates as a subsidiary of Lee's Pharmaceutical Holdings Limited.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Discovery | ANSN | 1997-08-26 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.01
0.00 (-8.40%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
185.9K
Beta
1.60
Float Shares
33.71M
Free Float %
100.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -20.00% | -28.57% | -60.00% | -5.66% | -75.00% | -66.67% | -98.67% | -100.00% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
0.01
Ratings Trend (MoM)
| Rating | 2025-08 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-87.87
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+97.8% ★ Q3'25: +99.5% (vs Q3'24)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-15.5% ★ Q3'25: -9,979.4% (vs Q3'24)
-
Share dilution Biotechnology: -3.4%+1,121.2% Q3'25: +50.4% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.24× Q3'25: -0.10× (vs Q3'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2005 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 EPS Ana. |
Dec 2028 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
134.0K
est: 135.6K (-1.2%)
|
987.0K
est: 407.0K (+142.5%)
|
2.04M
est: 1.64M (+24.4%)
|
1.49M
est: 2.17M (-31.4%)
|
1.79M
est: 2.27M (-21.4%)
|
198.0K
est: 26.16M (-99.2%)
|
—
est: 150.0K (-100.0%)
|
—
est: 2.00M (-100.0%)
|
12.20M
est.
|
12.40M
12.40M – 12.40M
+1.6% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| EBITDA |
-57.16M
est: -52.13M (-9.6%)
|
-49.88M
|
-36.72M
|
-16.39M
|
-18.97M
|
-25.87M
|
-39.46M
|
-1.47M
|
—
est.
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-42.51M
est: -53.23M (+20.1%)
|
-50.59M
|
-36.97M
|
-16.58M
|
-19.12M
|
-26.98M
|
-40.52M
|
-1.56M
|
—
est.
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-58.90M
est: -52.91M (-11.3%)
|
-55.17M
est: -17.49B (+99.7%)
|
-39.49M
est: -603.40B (+100.0%)
|
-18.45M
est: -349.26B (+100.0%)
|
-20.53M
est: -232.84B (+100.0%)
|
-27.48M
est: -613.34B (+100.0%)
|
-39.21M
est: -3.05B (+98.7%)
|
-5.49M
est: -9.10M (+39.7%)
|
-25.58M
est.
|
-28.87M
-28.87M – -28.87M
-12.8% YoY
|
-29.82M
-29.82M – -29.82M
-3.3% YoY
|
-37.3K
-37.3K – -37.3K
+99.9% YoY
|
| SGA |
18.51M
|
11.00M
|
8.37M
|
6.66M
|
7.42M
|
12.40M
|
10.79M
|
8.74M
|
—
est.
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-618,030,000.00
est: -3,343.07 (-18,486,827.4%)
|
-21,380,814.00
est: -332,640.00 (-6,327.6%)
|
-12,798,000.00
est: -11,475,000.00 (-11.5%)
|
-3,258,910.00
est: -6,642,000.00 (+50.9%)
|
-1,044,304.00
est: -4,428,000.00 (+76.4%)
|
-113,138.00
est: -11,664,000.00 (+99.0%)
|
-56,011.00
est: -58,050.00 (+3.5%)
|
-104.35
est: -173.00 (+39.7%)
|
-486.50
est.
|
-549.00
-549.00 – -549.00
-12.8% YoY
|
-567.00
-567.00 – -567.00
-3.3% YoY
|
-0.71
-0.71 – -0.71
+99.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-16.91M
OE per share TTM
-1,218.11
Owner's Yield
-4,463,078.06%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
661.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
41
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PharmaBio Development Inc. | 11.22M | 5.60% | — | — | — | — | CO | North Carolina | 2010-10-22 | ↗ |
| 2 | Dr. Jeffrey R. Jay, M.D. | 6.50M | 6.12% | — | 6.50M | — | — | IN | USA | 2015-07-28 | ↗ |
| 3 | Great Point Partners, LLC | 6.50M | 6.12% | — | 6.50M | — | — | IA | USA | 2015-07-28 | ↗ |
| 4 | Mr. David Kroin | 6.50M | 6.12% | — | 6.50M | — | — | IN | USA | 2015-07-28 | ↗ |
| 5 | Edward C. Johnson 3d | 5.65M | 13.00% | — | — | 5.65M | — | IN | Delaware | 2012-10-10 | ↗ |
| 6 | FMR LLC | 5.65M | 13.00% | — | — | 5.65M | — | HC | Delaware | 2012-10-10 | ↗ |
| 7 | HEARTLAND ADVISORS, INC. | 5.28M | 4.20% | — | 5.18M | — | 5.28M | IA | WISCONSIN USA | 2010-01-08 | ↗ |
| 8 | WILLIAM J. NASGOVITZ | 5.28M | 4.20% | — | 5.18M | — | 5.28M | IN | WISCONSIN USA | 2010-01-08 | ↗ |
| 9 | BARCLAYS GLOBAL INVESTORS, NA. | 3.62M | 5.81% | — | 5.23M | — | 5.23M | BK | Cayman Islands | 2015-11-19 | ↗ |
| 10 | Wells Fargo & Company | 3.32M | 8.05% | — | 3.50M | — | — | HC | Delaware | 2013-02-13 | ↗ |
| 11 | Wells Capital Management Incorporated | 3.31M | 7.61% | — | 2.28M | — | — | IA | California | 2013-02-13 | ↗ |
| 12 | (1) BlackRock, Inc. | 3.18M | 7.30% | 3.18M | — | 3.18M | — | HC | Delaware | 2013-01-30 | ↗ |
| 13 | Broadfin Capital, LLC | 3.17M | 5.77% | — | 3.17M | — | 3.17M | OO | Delaware | 2013-10-17 | ↗ |
| 14 | Broadfin Healthcare Master Fund, Ltd. | 3.17M | 5.77% | — | 3.17M | — | 3.17M | CO | Delaware | 2013-10-17 | ↗ |
| 15 | Kevin Kotler | 3.17M | 5.77% | — | 3.17M | — | 3.17M | HC, IN | Delaware | 2013-10-17 | ↗ |
| 16 | Center Laboratories, Inc. | 1.54M | 5.40% | 1.24M | 304.2K | 1.24M | 304.2K | CO | Taiwan | 2022-01-10 | ↗ |
| 17 | 94-3171940 | 1.21M | 42.80% | 1.21M | — | 1.21M | — | CO | Delaware | 1997-02-04 | ↗ |
| 18 | Deerfield Private Design International II, L.P. | 1.06M | 2.38% | — | 1.06M | — | — | PN | Delaware | 2013-02-22 | ↗ |
| 19 | Robert J. Capetola, Ph.D. | 620.0K | 13.81% | 620.0K | — | 620.0K | — | IN | United States | 1998-09-08 | ↗ |
| 20 | Deerfield Management Company, L.P. | 608.3K | 7.59% | — | 608.3K | — | — | PN | Delaware | 2024-02-01 | ↗ |
| 21 | Deerfield Mgmt, L.P. | 608.3K | 7.59% | — | 608.3K | — | — | PN | Delaware | 2024-02-01 | ↗ |
| 22 | James E. Flynn | 608.3K | 7.59% | — | 608.3K | — | — | IN | Delaware | 2024-02-01 | ↗ |
| 23 | 22-1024240 | 604.0K | 4.90% | — | 604.0K | — | 604.0K | CO | NEW JERSEY | 2000-03-10 | ↗ |
| 24 | U. S. Bancorp | 533.3K | 5.37% | — | 22.00M | — | 22.00M | — | USA | 2011-03-10 | ↗ |
| 25 | Jeff Easton | 475.1K | 9.90% | 475.1K | — | 475.1K | — | IN | Delaware | 2023-04-28 | ↗ |
| 26 | Lind Global Fund II LP | 475.1K | 9.90% | 475.1K | — | 475.1K | — | PN | Delaware | 2023-04-28 | ↗ |
| 27 | Lind Global Partners II LLC | 475.1K | 9.90% | 475.1K | — | 475.1K | — | OO | Delaware | 2023-04-28 | ↗ |
| 28 | Alex Noah Investors, Inc. | 459.0K | 9.99% | — | 459.0K | — | 459.0K | CO | Illinois | 2023-04-24 | ↗ |
| 29 | Jonathan I. Cope | 459.0K | 9.99% | — | 459.0K | — | 459.0K | IN | Illinois | 2023-04-24 | ↗ |
| 30 | Joshua B. Scheinfeld | 459.0K | 9.99% | — | 459.0K | — | 459.0K | IN | Illinois | 2023-04-24 | ↗ |
| 31 | Lincoln Park Capital Fund, LLC | 459.0K | 9.99% | — | 459.0K | — | 459.0K | OO | Illinois | 2023-04-24 | ↗ |
| 32 | Lincoln Park Capital, LLC | 459.0K | 9.99% | — | 459.0K | — | 459.0K | OO | Illinois | 2023-04-24 | ↗ |
| 33 | Rockledge Capital Corporation | 459.0K | 9.99% | — | 459.0K | — | 459.0K | OO | Illinois | 2023-04-24 | ↗ |
| 34 | Krishna Duvvuri | 326.9K | 6.35% | 326.9K | — | 326.9K | — | IN | U.S.A. | 2023-11-13 | ↗ |
| 35 | Deerfield PDI Financing II, L.P. | 324.8K | 4.05% | — | 324.8K | — | — | PN | Delaware | 2024-02-01 | ↗ |
| 36 | Deerfield Special Situations International Master Fund, L.P. | 308.9K | 0.70% | — | 308.9K | — | — | PN | Delaware | 2013-02-22 | ↗ |
| 37 | Deerfield Special Situations Fund, L.P. | 307.2K | 0.70% | — | 307.2K | — | — | PN | Delaware | 2013-02-22 | ↗ |
| 38 | Bioengine Capital Inc. | 304.2K | 1.10% | — | 304.2K | — | 304.2K | CO | Taiwan | 2022-01-10 | ↗ |
| 39 | Deerfield Private Design Fund II, L.P. | 283.5K | 3.54% | — | 283.5K | — | — | PN | Delaware | 2024-02-01 | ↗ |
| 40 | Armistice Capital, LLC | 270.0K | 7.12% | — | 270.0K | — | — | IA, OO | Delaware | 2024-11-14 | ↗ |
| 41 | Steven Boyd | 270.0K | 7.12% | — | 270.0K | — | — | HC, IN | Delaware | 2024-11-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BANK OF AMERICA CORP /DE/ | — -103.0 (-100.0%) | — -53.0 (-100.0%) | 0.00% -0.946 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 2 | JANE STREET GROUP, LLC | — -14.6K (-100.0%) | — -7.5K (-100.0%) | 0.00% -134.120 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 3 | SBI SECURITIES CO., LTD. | — -24.0 (-100.0%) | — -12.0 (-100.0%) | 0.00% -0.221 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 4 | TOWER RESEARCH CAPITAL LLC (TRC) | — -2.2K (-100.0%) | — -1.1K (-100.0%) | 0.00% -20.322 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 5 | UBS GROUP AG | — -22.0 (-100.0%) | — -11.0 (-100.0%) | 0.00% -0.202 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-03 | KUCHARCHUK ANDREW ALBERT | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-01-08 | Kelly Leanne | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-08 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 5,431 | 0.91 | 4.9K | 8,638 | D | ↗ |
| 2024-08-13 | PELLETIER SAUNDRA L | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-13 | Latkin Jed | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-07-22 | Simonson Steven | Officer | A-Award | A | Warrants (Right to Buy) | 2,674 | 4.11 | 11.0K | 2,674 | — | ↗ |
| 2024-07-22 | Fraser Craig | Director / Officer | A-Award | A | Warrants (Right to Buy) | 4,011 | 4.11 | 16.5K | 4,011 | — | ↗ |
| 2023-09-27 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 1.02 | 2.5K | 57,877 | — | ↗ |
| 2023-09-26 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 2,500 | 0.90 | 2.3K | 55,377 | — | ↗ |
| 2023-08-24 | McAndrew Jamie | Officer | — | D | Employee Stock Option (Right to Buy) | 1 | 6,990.00 | 7.0K | 0 | — | ↗ |
| 2023-08-23 | Williams Leslie J. | Director | A-Award | A | Common Stock | 2,033 | 0.00 | — | 2,133 | — | ↗ |
| 2023-08-23 | Strobeck Mark | Director | A-Award | A | Common Stock | 2,300 | 0.00 | — | 2,300 | — | ↗ |
| 2023-08-23 | Simonson Steven | Officer | A-Award | A | Common Stock | 15,867 | 0.00 | — | 17,440 | — | ↗ |
| 2023-08-23 | SCOTT ROBERT A | Director | A-Award | A | Stock Option (Right to Buy) | 3,050 | 1.21 | 3.7K | 3,050 | — | ↗ |
| 2023-08-23 | Geffken Daniel E. | Director | A-Award | A | Common Stock | 2,033 | 0.00 | — | 2,175 | — | ↗ |
| 2023-08-23 | Fraser Craig | Director / Officer | A-Award | A | Common Stock | 45,867 | 0.00 | — | 52,877 | — | ↗ |
| 2023-08-23 | Curtis Eric | Officer | A-Award | A | Common Stock | 14,667 | 0.00 | — | 15,920 | — | ↗ |
| 2023-06-22 | Strobeck Mark | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-04-26 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 1,497 | 1.77 | 2.6K | 7,010 | — | ↗ |
| 2023-04-25 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 1,315 | 1.89 | 2.5K | 5,513 | — | ↗ |
| 2023-02-28 | Simonson Steven | Officer | F-InKind | D | Common Stock | 100 | 0.00 | — | 1,573 | — | ↗ |
| 2023-02-28 | Fraser Craig | Director / Officer | F-InKind | D | Common Stock | 334 | 0.00 | — | 4,198 | — | ↗ |
| 2023-02-28 | Curtis Eric | Officer | F-InKind | D | Common Stock | 99 | 0.00 | — | 1,253 | — | ↗ |
| 2023-02-28 | CARMAN DIANE | Officer | F-InKind | D | Common Stock | 99 | 0.00 | — | 1,227 | — | ↗ |
| 2023-02-22 | Huang James | Director | D-Return | D | Warrants (right to purchase) | 275,862 | 7.98 | 2.20M | 0 | — | ↗ |
| 2023-01-27 | Tattory John A | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-07-27 | Fraser Craig | Officer | P-Purchase | A | Common Stock | 2,500 | 0.38 | 949.75 | 226,558 | — | ↗ |
| 2022-07-26 | Hamill John P. | Officer | P-Purchase | A | Common Stock | 3,000 | 0.37 | 1.1K | 72,800 | — | ↗ |
| 2022-07-26 | Fraser Craig | Officer | P-Purchase | A | Common Stock | 2,500 | 0.37 | 935.00 | 224,058 | — | ↗ |
| 2022-06-30 | Fraser Craig | Officer | P-Purchase | A | Common Stock | 4,500 | 0.43 | 1.9K | 221,558 | — | ↗ |
| 2022-06-29 | Fraser Craig | Officer | P-Purchase | A | Common Stock | 7,000 | 0.42 | 2.9K | 217,058 | — | ↗ |
| 2022-06-07 | Williams Leslie J. | Director | A-Award | A | Stock Option (Right to Buy) | 7,500 | 0.47 | 3.5K | 7,500 | — | ↗ |
| 2022-06-07 | SCOTT ROBERT A | Director | A-Award | A | Common Stock | 5,000 | 0.00 | — | 5,000 | — | ↗ |
| 2022-06-07 | Huang James | Director | A-Award | A | Common Stock | 5,000 | 0.00 | — | 296,281 | — | ↗ |
| 2022-06-07 | Geffken Daniel E. | Director | A-Award | A | Common Stock | 5,000 | 0.00 | — | 7,069 | — | ↗ |
| 2022-03-16 | Fraser Craig | Officer | P-Purchase | A | Common Stock | 2,000 | 0.98 | 2.0K | 210,058 | — | ↗ |
| 2022-03-15 | Simonson Steven | Officer | P-Purchase | A | Common Stock | 5,000 | 1.00 | 5.0K | 83,602 | — | ↗ |
| 2022-03-15 | Fraser Craig | Officer | P-Purchase | A | Common Stock | 3,000 | 0.98 | 2.9K | 208,058 | — | ↗ |
| 2022-03-04 | Simonson Steven | Officer | A-Award | A | Common Stock | 66,300 | 0.00 | — | 78,602 | — | ↗ |
| 2022-03-04 | Hamill John P. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 99,600 | 1.02 | 101.6K | 99,600 | — | ↗ |
| 2022-03-04 | Fraser Craig | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 250,400 | 1.02 | 255.4K | 250,400 | — | ↗ |
| 2022-03-04 | Curtis Eric | Officer | A-Award | A | Common Stock | 66,300 | 0.00 | — | 67,591 | — | ↗ |
| 2022-03-04 | CARMAN DIANE | Officer | A-Award | A | Common Stock | 66,300 | 0.00 | — | 66,300 | — | ↗ |
| 2021-12-30 | Center Laboratories, Inc. | 10% Owner | P-Purchase | A | Common Stock | 1,239,088 | 1.60 | 1.98M | 1,239,088 | — | ↗ |
| 2021-12-30 | Bioengine Capital Inc. | 10% Owner | S-Sale | D | Common Stock | 1,239,088 | 1.60 | 1.98M | 0 | — | ↗ |
| 2021-11-19 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 930 | 1.60 | 1.5K | 38,158 | — | ↗ |
| 2021-11-18 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 930 | 1.61 | 1.5K | 37,228 | — | ↗ |
| 2021-10-22 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 3,000 | 1.90 | 5.7K | 36,298 | — | ↗ |
| 2021-10-19 | Huang James | Director | P-Purchase | A | Common Stock | 50,000 | 1.90 | 95.1K | 291,281 | — | ↗ |
| 2021-10-19 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 3,000 | 1.91 | 5.7K | 33,298 | — | ↗ |
| 2021-07-01 | CARMAN DIANE | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-15 | Huang James | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.28 | 34.2K | 15,000 | — | ↗ |
| 2021-06-15 | Geffken Daniel E. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.28 | 34.2K | 15,000 | — | ↗ |
| 2021-04-16 | Hamill John P. | Officer | P-Purchase | A | Common Stock | 1,000 | 2.07 | 2.1K | 3,500 | — | ↗ |
| 2021-04-16 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 2.09 | 2.1K | 30,298 | — | ↗ |
| 2021-04-15 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 2.24 | 2.2K | 29,298 | — | ↗ |
| 2021-04-07 | Curtis Eric | Officer | P-Purchase | A | Common Stock | 791 | 2.52 | 2.0K | 1,291 | — | ↗ |
| 2021-04-06 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 500 | 2.57 | 1.3K | 28,298 | — | ↗ |
| 2021-04-05 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 2.58 | 2.6K | 27,798 | — | ↗ |
| 2021-04-01 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 500 | 2.46 | 1.2K | 26,798 | — | ↗ |
| 2021-03-31 | Huang James | Director / 10% Owner | P-Purchase | A | Common Stock | 150,000 | 2.36 | 354.0K | 171,000 | — | ↗ |
| 2021-03-31 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 500 | 2.32 | 1.2K | 26,298 | — | ↗ |
| 2021-03-25 | Simonson Steven | Officer | P-Purchase | A | Common Stock Warrants | 1,500 | 3.60 | 5.4K | 1,500 | — | ↗ |
| 2021-03-25 | Hamill John P. | Officer | P-Purchase | A | Common Stock Warrants | 1,500 | 3.60 | 5.4K | 1,500 | — | ↗ |
| 2021-03-25 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock Warrants | 1,500 | 3.60 | 5.4K | 1,500 | — | ↗ |
| 2021-02-03 | Williams Leslie J. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-02-03 | Schreiber Brian D | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 5.50 | 82.5K | 15,000 | — | ↗ |
| 2021-02-03 | SCOTT ROBERT A | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 5.50 | 165.0K | 30,000 | — | ↗ |
| 2021-02-03 | PEACOCK BRUCE | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 5.50 | 82.5K | 15,000 | — | ↗ |
| 2021-02-03 | Loh Evan | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-02-03 | Leone John R | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 5.50 | 82.5K | 15,000 | — | ↗ |
| 2021-02-03 | Joseph Mahady M | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 5.50 | 82.5K | 15,000 | — | ↗ |
| 2021-02-03 | Huang James | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 5.50 | 82.5K | 15,000 | — | ↗ |
| 2021-02-03 | Geffken Daniel E. | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 5.50 | 82.5K | 15,000 | — | ↗ |
| 2021-01-22 | Simonson Steven | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 60,000 | 5.44 | 326.4K | 60,000 | — | ↗ |
| 2021-01-22 | Hamill John P. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 60,000 | 5.44 | 326.4K | 60,000 | — | ↗ |
| 2021-01-22 | Fraser Craig | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 143,250 | 5.44 | 779.3K | 143,250 | — | ↗ |
| 2021-01-22 | Curtis Eric | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 60,000 | 5.44 | 326.4K | 60,000 | — | ↗ |
| 2020-10-28 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 250 | 6.56 | 1.6K | 24,298 | — | ↗ |
| 2020-10-23 | Huang James | Director / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 6.67 | 6.7K | 21,000 | — | ↗ |
| 2020-10-09 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 250 | 5.83 | 1.5K | 24,048 | — | ↗ |
| 2020-10-08 | Curtis Eric | Officer | P-Purchase | A | Common Stock | 500 | 5.27 | 2.6K | 500 | — | ↗ |
| 2020-10-07 | Hamill John P. | Officer | P-Purchase | A | Common Stock | 1,000 | 5.27 | 5.3K | 1,000 | — | ↗ |
| 2020-10-07 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 250 | 5.17 | 1.3K | 23,798 | — | ↗ |
| 2020-07-29 | Curtis Eric | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 205,461 | 7.65 | 1.57M | 205,461 | — | ↗ |
| 2020-07-20 | Hamill John P. | Officer | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 211,000 | 6.98 | 1.47M | 211,000 | — | ↗ |
| 2020-06-24 | Center Laboratories, Inc. | 10% Owner | J-Other | D | SERIES F WARRANTS | 0 | 3.68 | — | 0 | — | ↗ |
| 2020-06-24 | Bioengine Capital Inc. | 10% Owner | J-Other | D | SERIES F WARRANTS | 0 | 3.68 | — | 0 | — | ↗ |
| 2020-06-04 | Huang James | Director / 10% Owner | P-Purchase | A | Common Stock | 12,000 | 7.32 | 87.9K | 20,000 | — | ↗ |
| 2020-06-03 | Huang James | Director / 10% Owner | P-Purchase | A | Common Stock | 200 | 7.42 | 1.5K | 8,000 | — | ↗ |
| 2020-05-22 | Templeton Mary B Esq | Officer | P-Purchase | A | Common Stock Warrants | 1,103 | 7.98 | 8.8K | 1,103 | — | ↗ |
| 2020-05-22 | Tattory John A | Officer | P-Purchase | A | Common Stock | 449 | 7.25 | 3.3K | 9,280 | — | ↗ |
| 2020-05-22 | Simonson Steven | Officer | P-Purchase | A | Common Stock Warrants | 517 | 7.98 | 4.1K | 517 | — | ↗ |
| 2020-05-22 | Schreiber Brian D | Director | P-Purchase | A | Common Stock | 2,069 | 7.25 | 15.0K | 2,069 | — | ↗ |
| 2020-05-22 | PEACOCK BRUCE | Director | P-Purchase | A | Common Stock Warrants | 3,500 | 7.98 | 27.9K | 3,500 | — | ↗ |
| 2020-05-22 | Leone John R | Director | P-Purchase | A | Common Stock | 2,069 | 7.25 | 15.0K | 7,473 | — | ↗ |
| 2020-05-22 | Joseph Mahady M | Director | P-Purchase | A | Common Stock Warrants | 2,069 | 7.98 | 16.5K | 2,069 | — | ↗ |
| 2020-05-22 | Huang James | Director / 10% Owner | P-Purchase | A | Common Stock | 275,862 | 7.25 | 2.00M | 2,336,853 | — | ↗ |
| 2020-05-22 | Geffken Daniel E. | Director | P-Purchase | A | Common Stock Warrants | 2,069 | 7.98 | 16.5K | 2,069 | — | ↗ |
| 2020-05-22 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock Warrants | 2,069 | 7.98 | 16.5K | 2,069 | — | ↗ |
| 2020-05-20 | Center Laboratories, Inc. | 10% Owner | P-Purchase | A | Common Stock | 55,172 | 7.25 | 400.0K | 1,239,088 | — | ↗ |
| 2020-05-20 | Bioengine Capital Inc. | 10% Owner | P-Purchase | A | Common Stock | 55,172 | 7.25 | 400.0K | 1,239,088 | — | ↗ |
| 2020-03-09 | Curtis Eric | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-02-18 | Huang James | Director / 10% Owner | P-Purchase | A | Common Stock | 400 | 3.84 | 1.5K | 23,400 | — | ↗ |
| 2020-02-11 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 250 | 4.10 | 1.0K | 63,590 | — | ↗ |
| 2020-02-10 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 250 | 4.10 | 1.0K | 63,340 | — | ↗ |
| 2020-02-07 | Huang James | Director / 10% Owner | P-Purchase | A | Common Stock | 500 | 4.05 | 2.0K | 23,000 | — | ↗ |
| 2020-02-04 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 500 | 4.24 | 2.1K | 63,090 | — | ↗ |
| 2020-02-03 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 100 | 4.20 | 420.00 | 62,590 | — | ↗ |
| 2020-01-17 | Huang James | Director / 10% Owner | P-Purchase | A | Common Stock | 2,000 | 4.18 | 8.4K | 22,500 | — | ↗ |
| 2020-01-16 | Huang James | Director / 10% Owner | P-Purchase | A | Common Stock | 58 | 4.20 | 243.60 | 20,500 | — | ↗ |
| 2019-12-31 | Huang James | Director / 10% Owner | P-Purchase | A | Common Stock | 15,442 | 4.05 | 62.5K | 20,442 | — | ↗ |
| 2019-12-30 | Huang James | Director / 10% Owner | P-Purchase | A | Common Stock | 909 | 3.81 | 3.5K | 5,000 | — | ↗ |
| 2019-12-27 | Huang James | Director / 10% Owner | P-Purchase | A | Common Stock | 4,091 | 3.73 | 15.3K | 4,091 | — | ↗ |
| 2019-12-06 | Lee's Pharmaceutical Holdings Ltd | 10% Owner | P-Purchase | A | Common Stock | 1,655,629 | 3.02 | 5.00M | 14,450,599 | — | ↗ |
| 2019-12-06 | LPH II Investments Ltd | 10% Owner | P-Purchase | A | Common Stock | 1,655,629 | 3.02 | 5.00M | 4,008,234 | — | ↗ |
| 2019-12-06 | Huang James | Director / 10% Owner | P-Purchase | A | Series I Warrants | 827,815 | 4.03 | 3.34M | 827,815 | — | ↗ |
| 2019-06-28 | PEACOCK BRUCE | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 4.60 | 184.0K | 40,000 | — | ↗ |
| 2019-06-28 | Leone John R | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 4.60 | 184.0K | 40,000 | — | ↗ |
| 2019-06-28 | Joseph Mahady M | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 4.60 | 184.0K | 40,000 | — | ↗ |
| 2019-04-24 | Schreiber Brian D | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 60,000 | 4.32 | 259.2K | 60,000 | — | ↗ |
| 2019-04-24 | Huang James | Director / 10% Owner | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 60,000 | 4.32 | 259.2K | 60,000 | — | ↗ |
| 2019-04-24 | Geffken Daniel E. | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 60,000 | 4.32 | 259.2K | 60,000 | — | ↗ |
| 2019-03-19 | Templeton Mary B Esq | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 40,000 | 4.30 | 172.0K | 40,000 | — | ↗ |
| 2019-03-19 | Tattory John A | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 50,000 | 4.30 | 215.0K | 50,000 | — | ↗ |
| 2019-03-19 | Simonson Steven | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 50,000 | 4.30 | 215.0K | 50,000 | — | ↗ |
| 2019-03-19 | Fraser Craig | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 100,000 | 4.30 | 430.0K | 100,000 | — | ↗ |
| 2019-03-15 | Tattory John A | Officer | F-InKind | D | Common Stock | 10,281 | 0.00 | — | 25,922 | — | ↗ |
| 2019-03-15 | Simonson Steven | Officer | F-InKind | D | Common Stock | 9,824 | 0.00 | — | 30,011 | — | ↗ |
| 2019-03-15 | Fraser Craig | Director / Officer | F-InKind | D | Common Stock | 20,641 | 0.00 | — | 62,490 | — | ↗ |
| 2019-02-07 | Tattory John A | Officer | A-Award | A | Common Stock | 22,078 | 0.00 | — | 36,203 | — | ↗ |
| 2019-02-07 | Simonson Steven | Officer | D-Return | D | Common Stock | 23,514 | 0.00 | — | 16,321 | — | ↗ |
| 2019-02-07 | Fraser Craig | Director / Officer | F-InKind | D | Common Stock | 16,404 | 0.00 | — | 83,131 | — | ↗ |
| 2019-01-02 | Panacea Venture Healthcare Fund I, L.P. | 10% Owner | — | I | Series D Warrants | 187,500 | 4.00 | 750.0K | 0 | — | ↗ |
| 2019-01-02 | Huang James | Director / 10% Owner | — | I | Series D Warrants | 187,500 | 4.00 | 750.0K | 0 | — | ↗ |
| 2018-12-28 | Tattory John A | Officer | F-InKind | D | Common Stock | 8,007 | 5.00 | 40.0K | 36,203 | — | ↗ |
| 2018-12-28 | Simonson Steven | Officer | F-InKind | D | Common Stock | 7,402 | 5.00 | 37.0K | 39,835 | — | ↗ |
| 2018-12-28 | Fraser Craig | Director / Officer | F-InKind | D | Common Stock | 15,553 | 5.00 | 77.8K | 83,982 | — | ↗ |
| 2018-12-24 | Templeton Mary B Esq | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 421,906 | 4.22 | 1.78M | 421,906 | — | ↗ |
| 2018-12-24 | Tattory John A | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 738,335 | 4.22 | 3.12M | 738,335 | — | ↗ |
| 2018-12-24 | Simonson Steven | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 738,335 | 4.22 | 3.12M | 738,335 | — | ↗ |
| 2018-12-24 | PEACOCK BRUCE | Director | A-Award | A | Common Stock | 15,000 | 0.00 | — | 16,160 | — | ↗ |
| 2018-12-24 | Leone John R | Director | A-Award | A | Stock Option (Right to Buy) | 32,000 | 4.22 | 135.0K | 32,000 | — | ↗ |
| 2018-12-24 | Joseph Mahady M | Director | A-Award | A | Common Stock | 15,000 | 0.00 | — | 16,160 | — | ↗ |
| 2018-12-24 | Huang James | Director / 10% Owner | — | I | Series G Warrants | 1,494,024 | 4.05 | 6.05M | 0 | — | ↗ |
| 2018-12-24 | Fraser Craig | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 1,265,717 | 4.22 | 5.34M | 1,265,717 | — | ↗ |
| 2018-12-24 | Bioengine Capital Inc. | 10% Owner | — | D | SERIES G WARRANTS | 747,012 | 4.05 | 3.03M | 0 | — | ↗ |
| 2018-12-21 | Schreiber Brian D | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-12-21 | Panacea Venture Healthcare Fund I, L.P. | 10% Owner | — | D | Series F Warrants | 769,649 | 3.68 | 2.83M | 0 | — | ↗ |
| 2018-12-21 | Lee's Pharmaceutical Holdings Ltd | 10% Owner | P-Purchase | A | Series G Warrants | 597,610 | 4.05 | 2.42M | 1,042,224 | — | ↗ |
| 2018-12-21 | LPH II Investments Ltd | 10% Owner | P-Purchase | A | Series F Warrants | 307,859 | 3.68 | 1.13M | 1,040,886 | — | ↗ |
| 2018-12-21 | Ivy Blue Holdings Ltd | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,336,790 | — | ↗ |
| 2018-12-21 | Huang James | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 114,415 | — | ↗ |
| 2018-12-21 | China Cardiovascular Focus Ltd | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 8,063,861 | — | ↗ |
| 2018-12-21 | Bioengine Capital Inc. | 10% Owner | — | D | COMMON STOCK | 0 | 0.00 | — | 3,551,750 | — | ↗ |
| 2018-11-21 | Simonson Steven | Officer | C-Conversion | A | Common Stock | 150 | 1,495.00 | 224.3K | 47,237 | — | ↗ |
| 2018-11-21 | PEACOCK BRUCE | Director | C-Conversion | A | Common Stock | 850 | 1,495.00 | 1.27M | 1,160 | — | ↗ |
| 2018-11-21 | Leone John R | Director | C-Conversion | D | Series A Convertible Preferred Stock | 13 | 27.40 | 356.20 | 0 | — | ↗ |
| 2018-11-21 | Joseph Mahady M | Director | C-Conversion | D | Series A Convertible Preferred Stock | 17 | 27.40 | 465.80 | 0 | — | ↗ |
| 2018-11-21 | Fraser Craig | Director / Officer | C-Conversion | D | Series A Convertible Preferred Stock | 7 | 27.40 | 191.80 | 0 | — | ↗ |
| 2018-11-08 | Lee's Pharmaceutical Holdings Ltd | 10% Owner | C-Conversion | D | Series A Convertible Preferred Stock | 1,338 | 0.00 | — | 136,755 | — | ↗ |
| 2018-10-04 | LPH II Investments Ltd | 10% Owner | — | D | Series C Warrant | 135,417 | 5.52 | 747.5K | 0 | — | ↗ |
| 2018-04-04 | Lee's Pharmaceutical Holdings Ltd | 10% Owner | P-Purchase | A | Common Stock | 541,667 | 4.80 | 2.60M | 2,853,271 | — | ↗ |
| 2018-04-04 | LPH II Investments Ltd | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 541,667 | — | ↗ |
| 2017-11-01 | Tattory John A | Officer | A-Award | A | Common Stock | 883,144 | 0.00 | — | 884,215 | — | ↗ |
| 2017-11-01 | Simonson Steven | Officer | A-Award | A | Common Stock | 940,564 | 0.00 | — | 941,756 | — | ↗ |
| 2017-11-01 | Lee's Pharmaceutical Holdings Ltd | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 46,232,085 | — | ↗ |
| 2017-11-01 | LPH Investments Ltd | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 46,232,085 | — | ↗ |
| 2017-11-01 | Fraser Craig | Director / Officer | A-Award | A | Common Stock | 1,976,190 | 0.00 | — | 1,983,690 | — | ↗ |
| 2017-08-15 | Lee's Pharmaceutical Holdings Ltd | 10% Owner | — | D | Series A-1 Warrants | 1,338,000 | 1.37 | 1.83M | 0 | — | ↗ |
| 2017-03-01 | Templeton Mary B Esq | Officer | A-Award | A | Incentive Stock Option (Right to Buy) | 50,000 | 1.23 | 61.5K | 50,000 | — | ↗ |
| 2017-03-01 | Tattory John A | Officer | A-Award | A | Incentive Stock Option (Right to Buy) | 43,761 | 1.23 | 53.8K | 43,761 | — | ↗ |
| 2017-03-01 | Simonson Steven | Officer | A-Award | A | Incentive Stock Option (Right to Buy) | 36,666 | 1.23 | 45.1K | 36,666 | — | ↗ |
| 2017-03-01 | Fraser Craig | Director / Officer | A-Award | A | Incentive Stock Option (Right to Buy) | 100,000 | 1.23 | 123.0K | 100,000 | — | ↗ |
| 2017-02-15 | Lee's Pharmaceutical Holdings Ltd | 10% Owner | — | D | Series A Convertible Preferred Stock | 1,338,000 | 1.37 | 1.83M | 0 | — | ↗ |
| 2017-02-13 | Simonson Steven | Officer | P-Purchase | A | Series A Convertible Preferred Stock | 3 | 1.37 | 4.11 | 3 | — | ↗ |
| 2017-02-13 | PEACOCK BRUCE | Director | P-Purchase | A | Series A Convertible Preferred Stock | 17 | 1.37 | 23.29 | 17 | — | ↗ |
| 2017-02-13 | Leone John R | Director | P-Purchase | A | Series A Convertible Preferred Stock | 13 | 1.37 | 17.81 | 13 | — | ↗ |
| 2017-02-13 | Joseph Mahady M | Director | P-Purchase | A | Series A-1 Warrants (Right to Buy) | 17,000 | 1.37 | 23.3K | 17,000 | — | ↗ |
| 2017-02-13 | Fraser Craig | Director / Officer | P-Purchase | A | Series A-1 Warrants (Right to Buy) | 7,000 | 1.37 | 9.6K | 7,000 | — | ↗ |
| 2016-10-28 | Fraser Craig | Director / Officer | P-Purchase | A | Common Stock | 7,500 | 2.05 | 15.4K | 7,500 | — | ↗ |
| 2016-08-04 | ROSENTHALE MARVIN E | Director | A-Award | A | Common Stock | 4,348 | 0.00 | — | 6,211 | — | ↗ |
| 2016-08-04 | PEACOCK BRUCE | Director | A-Award | A | Common Stock | 4,348 | 0.00 | — | 6,211 | — | ↗ |
| 2016-08-04 | Leone John R | Director | A-Award | A | Common Stock | 4,348 | 0.00 | — | 11,250 | — | ↗ |
| 2016-08-04 | Joseph Mahady M | Director | A-Award | A | Common Stock | 4,348 | 0.00 | — | 6,211 | — | ↗ |
| 2016-07-28 | Templeton Mary B Esq | Officer | A-Award | A | Incentive Stock Option (Right to Buy) | 10,000 | 1.77 | 17.7K | 10,000 | — | ↗ |
| 2016-07-28 | Tattory John A | Officer | A-Award | A | Incentive Stock Option (Right to Buy) | 16,666 | 1.77 | 29.5K | 16,666 | — | ↗ |
| 2016-07-28 | Simonson Steven | Officer | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 16,667 | 1.77 | 29.5K | 16,667 | — | ↗ |
| 2016-07-28 | Fraser Craig | Director / Officer | A-Award | A | Incentive Stock Option (Right to Buy) | 40,000 | 1.77 | 70.8K | 40,000 | — | ↗ |
| 2016-06-30 | Templeton Mary B Esq | Officer | A-Award | A | Common Stock | 1,166 | 1.93 | 2.3K | 9,270 | — | ↗ |
| 2016-06-30 | Tattory John A | Officer | A-Award | A | Common Stock | 1,088 | 1.93 | 2.1K | 6,555 | — | ↗ |
| 2016-06-30 | Simonson Steven | Officer | A-Award | A | Common Stock | 1,166 | 1.93 | 2.3K | 6,884 | — | ↗ |
| 2016-06-30 | Fraser Craig | Director / Officer | A-Award | A | Common Stock | 1,078 | 1.93 | 2.1K | 1,078 | — | ↗ |
| 2016-03-31 | Templeton Mary B Esq | Officer | A-Award | A | Common Stock | 1,347 | 1.67 | 2.2K | 8,104 | — | ↗ |
| 2016-03-31 | Tattory John A | Officer | A-Award | A | Common Stock | 1,077 | 1.67 | 1.8K | 5,467 | — | ↗ |
| 2016-03-31 | Simonson Steven | Officer | A-Award | A | Common Stock | 1,347 | 1.67 | 2.2K | 5,718 | — | ↗ |
| 2016-02-01 | Templeton Mary B Esq | Officer | A-Award | A | Incentive Stock Option (Right to Buy) | 10,714 | 2.33 | 25.0K | 10,714 | — | ↗ |
| 2016-02-01 | Tattory John A | Officer | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 7,720 | 2.33 | 18.0K | 7,720 | — | ↗ |
| 2016-02-01 | Simonson Steven | Officer | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 23,797 | 2.33 | 55.4K | 23,797 | — | ↗ |
| 2016-02-01 | Fraser Craig | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
33.71M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Craig E. Fraser Former President and CEO | 568.4K | — | — | — | — | 14.9K | 583.3K | 0.00% | ↗ |
| 2 | 2024 | Steven G. Simonson, M.D. Senior Vice President and CMO | 458.1K | — | — | — | — | 10.4K | 468.5K | 0.00% | ↗ |
| 3 | 2024 | Eric Curtis Senior Vice President and COO | 401.4K | — | — | — | — | 10.1K | 411.5K | 0.00% | ↗ |
| 4 | 2024 | Jed Latkin President and CEO | 46.4K | — | — | — | — | 22.6K | 69.0K | 0.00% | ↗ |
| 5 | 2023 | Craig E. Fraser President and CEO | 557.3K | — | 55.5K | 70.9K | — | 9.9K | 693.6K | 18.23% | ↗ |
| 6 | 2023 | Craig E. Fraser Former President and CEO | 557.3K | — | 55.5K | 70.9K | — | 9.9K | 693.6K | 18.23% | ↗ |
| 7 | 2023 | Diane Carman Former Senior Vice President and General Counsel | 220.9K | — | — | — | — | 439.6K | 660.6K | 0.00% | ↗ |
| 8 | 2023 | Steven G. Simonson, M.D. Senior Vice President and CMO | 438.1K | — | 19.2K | 24.5K | — | 9.9K | 491.7K | 8.89% | ↗ |
| 9 | 2023 | Eric Curtis Senior Vice President and COO | 401.4K | — | 17.7K | 22.7K | — | 9.9K | 451.7K | 8.95% | ↗ |
| 10 | 2022 | Craig E. Fraser President and CEO | 544.6K | — | 170.2K | 216.9K | — | 9.2K | 940.9K | 41.15% | ↗ |
| 11 | 2022 | Steven G. Simonson, M.D. Senior VP and CMO | 435.0K | — | 67.6K | 86.3K | — | 11.2K | 600.0K | 25.65% | ↗ |
| 12 | 2022 | Steven G. Simonson, M.D. Senior Vice President and CMO | 435.0K | — | 67.6K | 86.3K | — | 9.2K | 598.0K | 25.74% | ↗ |
| 13 | 2022 | John P. Hamill Former Senior VP, CFO, Treasurer and Corporate Secretary | 398.0K | — | 67.6K | 86.3K | — | 9.2K | 561.1K | 27.43% | ↗ |
| 14 | 2021 | Craig E. Fraser President and CEO | 479.9K | 96.0K | — | 1.29M | — | 8.7K | 1.88M | 68.86% | ↗ |
| 15 | 2021 | Steven G. Simonson, M.D. Senior VP and CMO | 418.2K | 85.3K | — | 508.0K | — | 10.8K | 1.02M | 49.69% | ↗ |
| 16 | 2021 | John P. Hamill Senior VP, CFO, and Corporate Secretary | 380.2K | 83.6K | — | 270.7K | — | 8.7K | 743.2K | 36.42% | ↗ |
| 17 | 2021 | John P. Hamill Former Senior VP, CFO, Treasurer and Corporate Secretary | 380.2K | 83.6K | — | 270.7K | — | 8.7K | 743.2K | 36.42% | ↗ |
| 18 | 2020 | Eric Curtis Senior VP and Chief Operating Officer | 308.3K | 92.5K | — | 1.30M | — | 52.3K | 1.76M | 74.20% | ↗ |
| 19 | 2020 | John P. Hamill Senior VP, Chief Financial Officer and Corporate Secretary | 167.0K | 85.0K | — | 1.22M | — | 4.3K | 1.48M | 82.66% | ↗ |
| 20 | 2020 | John P. Hamill Senior VP, CFO, and Corporate Secretary | 167.0K | 85.0K | — | 1.22M | — | 4.3K | 1.48M | 82.66% | ↗ |
| 21 | 2020 | Craig Fraser President and Chief Executive Officer | 460.3K | 299.9K | — | — | — | 9.8K | 770.0K | 0.00% | ↗ |
| 22 | 2020 | Craig E. Fraser President and CEO | 460.3K | 299.9K | — | — | — | 9.8K | 770.0K | 0.00% | ↗ |
| 23 | 2020 | Steven G. Simonson, M.D. Senior VP and CMO | 393.5K | 237.7K | — | — | — | 18.8K | 650.0K | 0.00% | ↗ |
| 24 | 2019 | Craig Fraser President and Chief Executive Officer | 452.4K | 226.0K | 31.7K | 345.1K | — | 8.4K | 1.06M | 35.43% | ↗ |
| 25 | 2016 | John G. Cooper Former President and Chief Executive Officer | 34.8K | — | — | 225.4K | — | 667.5K | 927.8K | 24.30% | ↗ |
| 26 | 2016 | Craig Fraser President and Chief Executive Officer | 381.0K | — | — | 376.6K | — | 6.2K | 763.8K | 49.30% | ↗ |
| 27 | 2016 | Steven G. Simonson, M.D. Senior Vice President and Chief Medical Officer | 329.2K | — | — | 87.6K | — | 12.0K | 428.7K | 20.42% | ↗ |
| 28 | 2016 | John A. Tattory Senior Vice President, Chief Financial Officer and Treasurer | 288.2K | — | — | 67.6K | — | 8.1K | 363.8K | 18.57% | ↗ |
| 29 | 2015 | John G. Cooper Former President and Chief Executive Officer | 400.0K | 150.0K | — | 308.8K | — | 18.0K | 876.8K | 35.22% | ↗ |
| 30 | 2015 | John G. Cooper President and Chief Executive Officer | 400.0K | 150.0K | — | 308.8K | — | 18.0K | 876.8K | 35.22% | ↗ |
| 31 | 2015 | Steven G. Simonson, M.D. Senior Vice President and Chief Development Officer | 315.0K | 100.0K | — | 242.6K | — | 18.0K | 675.6K | 35.91% | ↗ |
| 32 | 2015 | Steven G. Simonson, M.D. Senior Vice President and Chief Medical Officer | 315.0K | 100.0K | — | 242.6K | — | 18.0K | 675.6K | 35.91% | ↗ |
| 33 | 2015 | John A. Tattory Senior Vice President, Chief Financial Officer and Treasurer | 265.9K | 77.0K | — | 132.3K | — | 10.9K | 486.1K | 27.23% | ↗ |
| 34 | 2015 | Thomas F. Miller, Ph.D., MBA Former Senior Vice President and Chief Operating Officer | 447.6K | 30.7K | — | — | — | 3.4K | 481.6K | 0.00% | ↗ |
| 35 | 2014 | John G. Cooper President and Chief Executive Officer | 400.0K | — | — | 206.4K | — | 17.5K | 623.9K | 33.08% | ↗ |
| 36 | 2014 | Thomas F. Miller, Ph.D., MBA Former Senior Vice President and Chief Operating Officer | 325.0K | — | — | 123.8K | — | 17.5K | 466.3K | 26.56% | ↗ |
| 37 | 2014 | John A. Tattory Senior Vice President, Chief Financial Officer and Treasurer | 253.5K | — | — | 185.8K | — | 15.6K | 454.9K | 40.84% | ↗ |
| 38 | 2014 | Thomas F. Miller, Ph.D., MBA Senior Vice President and Chief Operating Officer | 325.0K | — | — | 123.8K | — | — | 448.8K | 27.59% | ↗ |
| 39 | 2014 | John A. Tattory Senior Vice President and Chief Financial Officer | 253.5K | — | — | 185.8K | — | — | 439.3K | 42.29% | ↗ |
| 40 | 2014 | Russell G. Clayton, D.O. Senior Vice President, Research and Development | 264.5K | — | — | 92.9K | — | 45.7K | 403.1K | 23.04% | ↗ |
| 41 | 2014 | Steven G. Simonson, M.D. Senior Vice President and Chief Development Officer | 186.4K | — | — | 163.2K | — | 7.4K | 357.0K | 45.72% | ↗ |
| 42 | 2014 | Thomas C. Hoy Vice President, Manufacturing Operations Former Named Executive Officer | 249.3K | — | — | 92.9K | — | — | 342.1K | 27.15% | ↗ |
| 43 | 2013 | John G. Cooper President and Chief Executive Officer | 399.5K | 93.8K | — | 649.4K | — | — | 1.14M | 56.83% | ↗ |
| 44 | 2013 | John G. Cooper President, Chief Executive Officer and Chief Financial | 399.5K | 93.8K | — | 649.4K | — | — | 1.14M | 56.83% | ↗ |
| 45 | 2013 | Thomas F. Miller Senior Vice President and Chief Operating Officer | 321.3K | 59.0K | — | 371.1K | — | — | 751.4K | 49.39% | ↗ |
| 46 | 2013 | Thomas F. Miller, Ph.D., MBA Senior Vice President and Chief Operating Officer | 321.3K | 59.0K | — | 371.1K | — | — | 751.4K | 49.39% | ↗ |
| 47 | 2013 | Russell G. Clayton, D.O. Senior Vice President, Research and Development | 285.1K | 51.1K | — | 278.3K | — | — | 614.6K | 45.29% | ↗ |
| 48 | 2013 | Russell G. Clayton Senior Vice President Research and Development | 285.1K | 51.1K | — | 278.3K | — | — | 614.6K | 45.29% | ↗ |
| 49 | 2013 | Mary B. Templeton, Esq. Senior Vice President, General Counsel and Corporate Secretary | 265.9K | 37.6K | — | 148.4K | — | — | 451.9K | 32.85% | ↗ |
| 50 | 2012 | W. Thomas Amick Former Chairman of the Board and Chief Executive Officer | 410.0K | 205.0K | — | 488.4K | — | 1.35M | 2.45M | 19.94% | ↗ |
| 51 | 2012 | John G. Cooper President, Chief Financial Officer and Treasurer | 331.7K | 130.0K | — | 276.1K | — | 17.0K | 754.7K | 36.58% | ↗ |
| 52 | 2012 | John G. Cooper President, Chief Executive Officer and Chief Financial | 331.7K | 130.0K | — | 276.1K | — | — | 737.7K | 37.42% | ↗ |
| 53 | 2012 | John G. Cooper President and Chief Executive Officer | 331.7K | 130.0K | — | 276.1K | — | — | 737.7K | 37.42% | ↗ |
| 54 | 2012 | Thomas F. Miller, Ph.D., MBA Senior Vice President and Chief Operating Officer | 306.7K | 100.0K | — | 212.4K | — | — | 619.0K | 34.30% | ↗ |
| 55 | 2012 | Thomas F. Miller Senior Vice President and Chief Operating Officer | 306.7K | 100.0K | — | 212.4K | — | — | 619.0K | 34.30% | ↗ |
| 56 | 2012 | Russell G. Clayton Senior Vice President Research and Development | 273.3K | 105.0K | — | 169.9K | — | — | 548.2K | 30.99% | ↗ |
| 57 | 2012 | Mary B. Templeton, Esq. Senior Vice President, General Counsel and Corporate Secretary | 258.3K | 80.0K | — | 116.8K | — | — | 455.1K | 25.66% | ↗ |
| 58 | 2011 | W. Thomas Amick Chairman of the Board and Chief Executive Officer | 400.0K | 15.0K | — | 584.2K | — | 84.7K | 1.08M | 53.90% | ↗ |
| 59 | 2011 | W. Thomas Amick Former Chairman of the Board and Chief Executive Officer | 400.0K | 15.0K | — | 584.2K | — | 84.7K | 1.08M | 53.90% | ↗ |
| 60 | 2011 | John G. Cooper President, Chief Financial Officer and Treasurer | 325.0K | 15.0K | — | 365.1K | — | 16.5K | 721.6K | 50.60% | ↗ |
| 61 | 2011 | John G. Cooper President, Chief Executive Officer and Chief Financial | 325.0K | 15.0K | — | 365.1K | — | — | 705.1K | 51.78% | ↗ |
| 62 | 2011 | Thomas F. Miller Senior Vice President and Chief Operating Officer | 300.0K | 40.0K | — | 292.1K | — | — | 632.1K | 46.21% | ↗ |
| 63 | 2011 | Russell G. Clayton Senior Vice President Research and Development | 261.7K | 45.0K | — | 182.6K | — | — | 489.2K | 37.32% | ↗ |
| 64 | 2011 | Mary B. Templeton, Esq. Senior Vice President, General Counsel and Corporate Secretary | 243.9K | 15.0K | — | 146.1K | — | — | 404.9K | 36.07% | ↗ |
| 65 | 2010 | W. Thomas Amick Chairman of the Board and Chief Executive Officer | 330.3K | — | 92.0K | 4.3K | — | 45.0K | 471.6K | 20.41% | ↗ |
| 66 | 2010 | John G. Cooper President, Chief Financial Officer and Treasurer | 313.4K | 50.0K | 66.0K | — | — | 8.3K | 437.6K | 15.08% | ↗ |
| 67 | 2010 | David L. Lopez, Esq., CPA Executive Vice President, General Counsel, Chief Compliance Officer and Secretary | 307.0K | — | 49.5K | — | — | 8.1K | 364.6K | 13.58% | ↗ |
| 68 | 2010 | Thomas F. Miller Senior Vice President and Chief Operating Officer | 267.7K | — | 49.5K | — | — | 8.3K | 325.5K | 15.21% | ↗ |
| 69 | 2009 | Robert J. Capetola, Ph.D Former President and Chief Executive Officer | 306.3K | — | — | 257.1K | — | 662.7K | 1.23M | 20.97% | ↗ |
| 70 | 2009 | John G. Cooper President, Chief Financial Officer and Treasurer | 307.0K | — | — | — | — | 8.3K | 315.3K | 0.00% | ↗ |
| 71 | 2009 | David L. Lopez, Esq., CPA Executive Vice President, General Counsel, Chief Compliance Officer and Secretary | 307.0K | — | — | — | — | 7.5K | 314.5K | 0.00% | ↗ |
| 72 | 2009 | David L. Lopez, Esq., CPA Executive Vice President, General Counsel, Chief Compliance Officer and Secretary Former Officer | 307.0K | — | — | — | — | 7.5K | 314.5K | 0.00% | ↗ |
| 73 | 2009 | W. Thomas Amick Chairman of the Board and Chief Executive Officer | 131.1K | — | — | 19.9K | — | 50.0K | 201.0K | 9.91% | ↗ |
| 74 | 2008 | Robert J. Capetola, Ph.D. President and Chief Executive Officer | 490.0K | — | 10.5K | 1.09M | — | 34.5K | 1.63M | 67.75% | ↗ |
| 75 | 2008 | Robert J. Capetola, Ph.D Former President and Chief Executive Officer | 490.0K | — | — | 566.4K | — | 34.5K | 1.09M | 51.92% | ↗ |
| 76 | 2008 | David L. Lopez, Esq., CPA Executive Vice President, General Counsel, Chief Compliance Officer and Secretary | 307.0K | — | 6.3K | 437.3K | — | — | 750.6K | 59.10% | ↗ |
| 77 | 2008 | John G. Cooper Executive Vice President, Chief Financial Officer and Treasurer | 307.0K | — | 6.3K | 429.9K | — | — | 743.2K | 58.69% | ↗ |
| 78 | 2008 | John G. Cooper President, Chief Financial Officer and Treasurer | 307.0K | — | — | 302.1K | — | 7.8K | 616.8K | 48.97% | ↗ |
| 79 | 2008 | Robert Segal, M.D., F.A.C.P. Senior Vice President, Medical and Scientific Affairs and Chief Medical Officer | 290.0K | — | 2.8K | 221.7K | — | — | 514.5K | 43.63% | ↗ |
| 80 | 2008 | David L. Lopez, Esq., CPA Executive Vice President, General Counsel, Chief Compliance Officer and Secretary Former Officer | 307.0K | — | — | 183.8K | — | 7.5K | 498.3K | 36.88% | ↗ |
| 81 | 2008 | Charles F. Katzer Senior Vice President, Manufacturing Operations | 250.0K | — | — | 216.3K | — | — | 466.3K | 46.39% | ↗ |
| 82 | 2008 | W. Thomas Amick Chairman of the Board and Chief Executive Officer | — | — | — | 39.5K | — | 50.0K | 89.5K | 44.14% | ↗ |
| 83 | 2007 | Robert J. Capetola, Ph.D. Chief Executive Officer and President | 470.0K | 300.0K | 25.7K | 1.35M | — | 29.6K | 2.18M | 63.30% | ↗ |
| 84 | 2007 | Robert J. Capetola, Ph.D. President and Chief Executive Officer | 470.0K | 300.0K | 25.7K | 1.35M | — | 29.6K | 2.18M | 63.30% | ↗ |
| 85 | 2007 | John G. Cooper Executive Vice President, Chief Financial Officer and Treasurer | 292.0K | 150.0K | 15.4K | 535.3K | — | — | 992.7K | 55.48% | ↗ |
| 86 | 2007 | David L. Lopez, Esq., CPA Executive Vice President, General Counsel, Chief Compliance Officer and Secretary | 290.0K | 152.0K | 15.4K | 526.3K | — | — | 983.7K | 55.07% | ↗ |
| 87 | 2007 | Robert Segal, M.D., F.A.C.P. Senior Vice President Medical and Scientific Affairs and Chief Medical Officer | 273.0K | 70.0K | 6.9K | 281.0K | — | 7.8K | 638.6K | 45.08% | ↗ |
| 88 | 2007 | Robert Segal, M.D., F.A.C.P. Senior Vice President, Medical and Scientific Affairs and Chief Medical Officer | 273.0K | 70.0K | 6.9K | 281.0K | — | — | 630.9K | 45.63% | ↗ |
| 89 | 2007 | Charles F. Katzer Senior Vice President, Manufacturing Operations | 225.0K | 70.0K | — | 246.0K | — | — | 541.0K | 45.48% | ↗ |
| 90 | 2006 | Robert J. Capetola, Ph.D. Chief Executive Officer and President | 470.0K | 150.0K | 52.4K | 1.04M | — | 34.4K | 1.75M | 62.55% | ↗ |
| 91 | 2006 | Robert J. Capetola, Ph.D. President and Chief Executive Officer | 470.0K | 150.0K | 52.4K | 1.04M | — | 34.4K | 1.75M | 62.55% | ↗ |
| 92 | 2006 | John G. Cooper Executive Vice President, Chief Financial Officer and Treasurer | 292.0K | 120.0K | 31.4K | 526.4K | — | — | 969.9K | 57.52% | ↗ |
| 93 | 2006 | Christopher J. Schaber, Ph.D. | 109.7K | — | 31.4K | 301.5K | — | 512.5K | 955.0K | 34.86% | ↗ |
| 94 | 2006 | David L. Lopez, Esq., CPA Executive Vice President, General Counsel, Chief Compliance Officer and Secretary | 290.0K | 120.0K | 31.4K | 498.1K | — | — | 939.5K | 56.36% | ↗ |
| 95 | 2006 | Mark G. Osterman | 88.3K | — | 20.9K | 153.6K | — | 358.0K | 620.8K | 28.11% | ↗ |
| 96 | 2006 | Robert Segal, M.D., F.A.C.P. Senior Vice President Medical and Scientific Affairs and Chief Medical Officer | 265.0K | 60.0K | 14.0K | 226.5K | — | 7.5K | 572.9K | 41.96% | ↗ |
| 97 | 2006 | Robert Segal, M.D., F.A.C.P. Senior Vice President, Medical and Scientific Affairs and Chief Medical Officer | 265.0K | 60.0K | 14.0K | 226.5K | — | — | 565.4K | 42.52% | ↗ |
| 98 | 2006 | Thomas F. Miller, Ph.D., MBA Senior Vice President Commercialization and Corporate Development Former Officers of the Company | 190.9K | 45.0K | 10.5K | 177.7K | — | 118.1K | 542.2K | 34.71% | ↗ |
| 99 | 2006 | Charles F. Katzer Senior Vice President, Manufacturing Operations | 213.5K | 80.0K | — | 149.2K | — | — | 442.6K | 33.70% | ↗ |
| 100 | 2005 | Robert J. Capetola, Ph.D. President, Chief Executive Officer and Director | 440.0K | 300.0K | — | 500.0K | — | 17.0K | 1.26M | 39.78% | ↗ |
| 101 | 2005 | Christopher J. Schaber, Ph.D. Exec. Vice President, Chief Operating Officer | 290.0K | 100.0K | — | 80.0K | — | 7.0K | 477.0K | 16.77% | ↗ |
| 102 | 2005 | John G. Cooper Exec. Vice President, Chief Financial Officer | 275.0K | 90.0K | — | 75.0K | — | 7.0K | 447.0K | 16.78% | ↗ |
| 103 | 2005 | David L. Lopez, Esq., CPA Exec. Vice President, General Counsel | 260.0K | 90.0K | — | 70.0K | — | 7.0K | 427.0K | 16.39% | ↗ |
| 104 | 2005 | Mark G. Osterman Senior Vice President, Sales & Marketing | 250.0K | 65.0K | — | 70.0K | — | 7.0K | 392.0K | 17.86% | ↗ |
| 105 | 2004 | Robert J. Capetola, Ph.D. President, Chief Executive Officer and Director | 390.0K | 325.0K | — | 538.0K | — | 16.5K | 1.27M | 42.38% | ↗ |
| 106 | 2004 | Christopher J. Schaber, Ph.D. Exec. Vice President, Chief Operating Officer | 250.0K | 150.0K | — | 275.0K | — | 6.5K | 681.5K | 40.35% | ↗ |
| 107 | 2004 | John G. Cooper Exec. Vice President, Chief Financial Officer | 240.0K | 100.0K | — | 275.0K | — | 6.5K | 621.5K | 44.25% | ↗ |
| 108 | 2004 | David L. Lopez, Esq., CPA Exec. Vice President, General Counsel | 230.0K | 100.0K | — | 200.0K | — | 6.5K | 536.5K | 37.28% | ↗ |
| 109 | 2004 | David L. Lopez, Esq., CPA Senior Vice President, General Counsel | 230.0K | 100.0K | — | 200.0K | — | 6.5K | 536.5K | 37.28% | ↗ |
| 110 | 2004 | Mark G. Osterman Senior Vice President, Sales & Marketing | 139.5K | 70.0K | — | 290.0K | — | 1.6K | 501.1K | 57.87% | ↗ |
| 111 | 2004 | Robert Segal, M.D., F.A.C.P. Senior Vice President, Chief Medical Officer | 237.0K | 75.0K | — | 145.0K | — | 6.5K | 463.5K | 31.28% | ↗ |
| 112 | 2003 | Robert J. Capetola, Ph.D President, Chief Executive Officer and Director | 314.0K | 275.0K | — | 365.0K | — | 16.0K | 970.0K | 37.63% | ↗ |
| 113 | 2003 | Robert J. Capetola, Ph.D. President, Chief Executive Officer and Director | 314.0K | 275.0K | — | 365.0K | — | 16.0K | 970.0K | 37.63% | ↗ |
| 114 | 2003 | Christopher J. Schaber, Ph.D. Exec. Vice President, Chief Operating Officer | 230.0K | 125.0K | — | 60.0K | — | 15.8K | 430.8K | 13.93% | ↗ |
| 115 | 2003 | Christopher J. Schaber, Ph.D Exec. Vice President, Chief Operating Officer | 230.0K | 125.0K | — | 60.0K | — | 15.8K | 430.8K | 13.93% | ↗ |
| 116 | 2003 | John G. Cooper Exec. Vice President, Chief Financial Officer | 203.0K | 85.0K | — | 80.0K | — | 6.0K | 374.0K | 21.39% | ↗ |
| 117 | 2003 | David L. Lopez, Esq., CPA Senior Vice President, General Counsel | 198.0K | 50.0K | — | 100.0K | — | 6.0K | 354.0K | 28.25% | ↗ |
| 118 | 2003 | David L. Lopez, Esq., CPA Exec. Vice President, General Counsel | 198.0K | 50.0K | — | 100.0K | — | 6.0K | 354.0K | 28.25% | ↗ |
| 119 | 2003 | Robert Segal, M.D., F.A.C.P. Senior Vice President, Chief Medical Officer | 228.0K | 60.0K | — | 35.0K | — | 6.0K | 329.0K | 10.64% | ↗ |
| 120 | 2003 | Robert Segal, MD Senior Vice President, Clinical Research & Chief Medical Officer | 228.0K | 60.0K | — | 35.0K | — | 6.0K | 329.0K | 10.64% | ↗ |
| 121 | 2003 | Deni M. Zodda, Ph.D Sr. Vice President, Business Development | 201.0K | 45.0K | — | 50.0K | — | 6.0K | 302.0K | 16.56% | ↗ |
| 122 | 2003 | Ralph Niven, Ph.D Sr. Vice President, Preclinical Development | 193.0K | 20.0K | — | 30.0K | — | 6.0K | 249.0K | 12.05% | ↗ |
| 123 | 2002 | Robert J. Capetola, Ph.D. President, Chief Executive Officer and Director | 304.0K | 125.0K | — | 250.0K | — | 10.0K | 689.0K | 36.28% | ↗ |
| 124 | 2002 | Robert J. Capetola, Ph.D President, Chief Executive Officer and Director | 304.0K | 125.0K | — | 250.0K | — | 10.0K | 689.0K | 36.28% | ↗ |
| 125 | 2002 | John G. Cooper Exec. Vice President, Chief Financial Officer | 192.0K | 60.0K | — | 215.0K | — | — | 467.0K | 46.04% | ↗ |
| 126 | 2002 | Christopher J. Schaber, Ph.D Exec. Vice President, Chief Operating Officer | 225.0K | 35.0K | — | 160.0K | — | 9.6K | 429.6K | 37.24% | ↗ |
| 127 | 2002 | Christopher J. Schaber, Ph.D. Exec. Vice President, Chief Operating Officer | 225.0K | 35.0K | — | 160.0K | — | 9.6K | 429.6K | 37.24% | ↗ |
| 128 | 2002 | John G. Cooper Sr. Vice President, Chief Financial Officer | 192.0K | 60.0K | — | 135.0K | — | — | 387.0K | 34.89% | ↗ |
| 129 | 2002 | Ralph Niven, Ph.D Sr. Vice President, Preclinical Development | 190.7K | 35.0K | — | 130.0K | — | 15.0K | 370.7K | 35.07% | ↗ |
| 130 | 2002 | Ralph Niven, Ph.D. Sr. Vice President, Preclinical Development | 190.7K | 50.0K | — | 110.0K | — | — | 350.7K | 31.37% | ↗ |
| 131 | 2002 | Deni M. Zodda, Ph.D Sr. Vice President, Business Development | 178.1K | 30.0K | — | 140.0K | — | — | 348.1K | 40.22% | ↗ |
| 132 | 2002 | Robert Segal, M.D., F.A.C.P. Senior Vice President, Chief Medical Officer | 222.6K | 20.0K | — | 100.0K | — | — | 342.6K | 29.19% | ↗ |
| 133 | 2002 | Robert Segal, MD Senior Vice President, Clinical Research & Chief Medical Officer | 222.6K | 20.0K | — | 100.0K | — | — | 342.6K | 29.19% | ↗ |
| 134 | 2002 | David L. Lopez, Esq., CPA Senior Vice President, General Counsel | 191.7K | 25.0K | — | 125.0K | — | — | 341.7K | 36.59% | ↗ |
| 135 | 2002 | Christopher J. Schaber Exec. Vice President, Chief Operating Officer | 225.0K | 35.0K | — | 60.0K | — | 9.6K | 329.6K | 18.20% | ↗ |
| 136 | 2002 | Deni M. Zodda, Ph.D. Sr. Vice President, Business Development | 178.1K | 30.0K | — | 60.0K | — | — | 268.1K | 22.38% | ↗ |
| 137 | 2001 | Robert J. Capetola, Ph.D. President, Chief Executive Officer and Director | 275.0K | 120.0K | — | 125.0K | — | 10.0K | 530.0K | 23.58% | ↗ |
| 138 | 2001 | Robert J. Capetola, Ph.D President, Chief Executive Officer and Director | 275.0K | 120.0K | — | 125.0K | — | 10.0K | 530.0K | 23.58% | ↗ |
| 139 | 2001 | Christopher J. Schaber, Ph.D Exec. Vice President, Chief Operating Officer | 210.0K | 60.0K | — | 70.0K | — | — | 340.0K | 20.59% | ↗ |
| 140 | 2001 | Christopher J. Schaber Exec. Vice President, Chief Operating Officer | 210.0K | 60.0K | — | 70.0K | — | — | 340.0K | 20.59% | ↗ |
| 141 | 2001 | Robert Segal, MD Senior Vice President, Clinical Research & Chief Medical Officer | 214.0K | 50.0K | — | 70.0K | — | — | 334.0K | 20.96% | ↗ |
| 142 | 2001 | Deni M. Zodda, Ph.D Sr. Vice President, Business Development | 182.0K | 56.0K | — | 80.0K | — | — | 318.0K | 25.16% | ↗ |
| 143 | 2001 | Deni M. Zodda, Ph.D. Sr. Vice President, Business Development | 182.0K | 56.0K | — | 80.0K | — | — | 318.0K | 25.16% | ↗ |
| 144 | 2001 | David L. Lopez, Esq., CPA Senior Vice President, General Counsel | 178.0K | 50.0K | — | 70.0K | — | — | 298.0K | 23.49% | ↗ |
| 145 | 2001 | John G. Cooper Exec. Vice President, Chief Financial Officer | 11.6K | — | — | 100.0K | — | — | 111.6K | 89.63% | ↗ |
| 146 | 2001 | John G. Cooper Sr. Vice President, Chief Financial Officer | 11.6K | — | — | 100.0K | — | — | 111.6K | 89.63% | ↗ |
| 147 | 2001 | Ralph Niven, Ph.D Sr. Vice President, Preclinical Development | 15.8K | — | — | 70.0K | — | — | 85.8K | 81.55% | ↗ |
| 148 | 2001 | Ralph Niven, Ph.D. Sr. Vice President, Preclinical Development | 15.8K | — | — | 70.0K | — | — | 85.8K | 81.55% | ↗ |
| 149 | 2000 | Robert J. Capetola, Ph.D. President, Chief Executive Officer and Director | 258.5K | 67.0K | — | 125.0K | — | — | 450.5K | 27.75% | ↗ |
| 150 | 2000 | Christopher J. Schaber Exec. Vice President, Chief Operating Officer | 195.3K | 74.5K | — | 74.5K | — | — | 344.3K | 21.64% | ↗ |
| 151 | 2000 | Deni M. Zodda, Ph.D. Sr. Vice President, Business Development | 51.0K | 36.0K | — | 70.0K | — | — | 157.0K | 44.59% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jed A. Latkin | Chief Executive Officer, President & Director | 143.7K | male |
| George Cox | Vice President of Technical Operations | — | male |
| Pratap Paruchuru | Executive Director of Clinical Development | — | — |
| Tracy Rarick | Head of Operations & Program Management | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for WINT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
